Phase 3 trial of aficamten, a cardiac myosin inhibitor, shows positive results for treating obstructive hypertrophic cardiomyopathy.
A phase 3 trial of aficamten, a cardiac myosin inhibitor, has reported positive results for treating obstructive hypertrophic cardiomyopathy (HCM). Aficamten improved exercise capacity, peak oxygen uptake, and reduced limiting symptoms in participants with obstructive HCM. The drug targets myosin to reduce left ventricular contractility, which leads to LVOT obstruction. Cytokinetics plans to file for FDA approval in Q3 and seek European Medicines Agency approval in Q4, aiming for a mid-2025 launch.
May 13, 2024
6 Articles